# Vaccination Report – 31 August 2021

# 1. Vaccine Implementation

• WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 19 August 2021)

	Manufacturer	Name of Vaccine	NRA of Record	Vaccine type	
1	Pfizer-BioNTech (US)	BNT162b2	EMA/USFDA	mRNA	
2	AstraZeneca (UK)	ChAdOx1 (AZS1222)	EMA/ MFDS KOREA/ Japan MHLW/PMDA/ Australia TGA	Non ReplicatingViral vector	
3	Serum Institute of India (India)	Covishield (ChAdOx1_nCoV-19) DCGI Non Re		Non Replicating Viral Vector	
4	Johnson &Johnson (US)	Ad26.CoV2.S	26.CoV2.S EMA Non Replica vector		
5	Moderna (US)	mRNA-1273	mRNA-1273 EMA/USFDA		
6	Sinopharm Beijing (China)	BBIBP-CorV	NMPA	Inactivated virus (Vero Cells)	
7	Sinovac (China)	SARS-CoV-2 Vaccine	NMPA	Inactivated virus (Vero Cell)	

• 22 Vaccines Approved by at Least One Country

Vaccine Type	mRNA	Non Replicating Viral vector	Inactivated virus	Protein Subunit	DNA	Total
In Use	3	6	8	4	1	22

Source: <a href="https://covid19.trackvaccines.org/vaccines/">https://covid19.trackvaccines.org/vaccines/</a> (Last Updated 23 August 2021)


• Vaccination against COVID-19 has now started in **217** locations

(Source: Our World in Data.Last Updated 26 Aug, 2021)

Location	Doses given	Fully vaccinated (% of population)	At least 1 dose (% of population)
Worldwide	5.13 billion	1.96 billion (24.91%)	2.59 billion (32.96%)

### About this data:

- a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.
- b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.
  - c: It only has full vaccination totals in some locations.



# Share of the population fully vaccinated against COVID-19 Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country. No data 0% 10% 20% 30% 40% 50% 60% 70% 80%

Source: Official data collated by Our World in Data – Last updated 27 August 2021, 11:40 (London time)

Note: This data is only available for countries which report the breakdown of doses administered by first and second doses. Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

Our Worldin Data.org/coronavirus - CC BY


### COVID-19 Vaccination Policy

- This metric records policies for vaccine delivery for different groups.

   Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups

   Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups

   Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for all three plus partial additional availability (select broad groups/ages)



Source: Hale, Angrist, Goldszmidt, Kira, Petherick, Phillips, Webster, Cameron-Blake, Hallas, Majumdar, and Tatlow (2021). "A global panel database of pandemic policies (Oxford COVID-19 Government ResponseTracker)." Nature Human Behaviour. — Last updated 27 August 2021, 01:50 (London time)

OurWorldInData.org/coronavirus • CC BY

# 2. Vaccine effectiveness against symptomatic infection for Alpha and Delta variants

Vaccine Status	Vaccine Ef	ectiveness	
	Alpha	Delta	
1 Dose (BNT162b2 or ChAdOx1 nCoV-19)	48.7% (95%CI: 45.5-51.7%) <sup>1</sup> 66%(BNT162b2) <sup>4</sup> 64% (ChAdOx1) <sup>4</sup>	30.7% (95%CI: 25.2-35.7%) <sup>1</sup> 56%(BNT162b2) <sup>4</sup> 67%(ChAdOx1) <sup>4</sup>	
1 Dose (mRNA-1273)	83%4	72%4	
1 Dose(Sinopharm or Sinovac)	Unknown	13.8%,(95%CI: -60.2-54.8%) <sup>3</sup>	
2 Doses (BNT162b2)	93.7% (95%CI: 91.6-95.3) <sup>1</sup> 76% (95%CI: 69-81%) <sup>2</sup> 89% <sup>4</sup>	88% (95%CI: 85.3-90.1%)1 42% (95% CI: 13-62%)2 87% <sup>4</sup>	
2 Doses (ChAdOx1 nCoV-19)	74.5% (95%CI: 68.4-79.4%) <sup>1</sup>	67.0% (95%CI: 61.3-71.8%) <sup>1</sup>	
2 Doses (mRNA-1273)	86%, (95%CI: 81-90.6%) <sup>2</sup>	76%, (95% CI: 58-87%) <sup>2</sup>	
2 Doses(Sinopharm or Sinovac)	Unknown	59.0%, (95%CI: 16.0-81.6%) <sup>3</sup>	

### References:

- 1) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- 2) Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
- 3) Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
- 4) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada



## 3. Latest Relevant Articles

 Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

### 4. Other Information

- CDC: Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1—August 1, 2021
- CDC: Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021